Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COPAD
- Development stage
- Phase 3
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
COPAD is a multi-agent chemotherapy regimen used primarily in the treatment of pediatric and young adult mature B-cell malignancies, including Burkitt lymphoma/leukemia, diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma (MLBCL), and B-cell acute lymphoblastic leukemia (B-ALL). Developed and studied by St. Jude Children's Research Hospital as part of the 'Mature B-Cell Lymphoma and Leukemia Study III' (SJBC3), the regimen is an acronym for its active components: cyclophosphamide, vincristine (Oncovin), prednisone (or prednisolone), doxorubicin (Adriamycin), and G-CSF (filgrastim or pegfilgrastim). COPAD is a combination cytotoxic chemotherapy regimen that targets rapidly dividing cancer cells through multiple mechanisms, including DNA alkylation, microtubule inhibition, and topoisomerase II inhibition. It was originally derived from the LMB-96 (Lymphome Malins de Burkitt) protocol and is specifically utilized for lower-risk (Group A) patients in risk-adapted clinical trials.
- Other names
- COPAD regimenSJBC3 Group A regimenSJBC-3 Group A regimenSJBC 3 Group A regimen
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on COPAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COPAD.